Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study
Status: NOT_YET_RECRUITING
Study type: OBSERVATIONAL
Conditions: Hormone-receptor-positive Breast Cancer|Premenopausal Breast Cancer|Breast Cancer Patients at Intermediate to High Risk|Ovarian Function Suppression Combined With Aromatase Inhibitor or Tamoxifen or Torimefen
Interventions: DRUG: Aromatase inhibitor|PROCEDURE: ovarian function suppression (Oophorectomy, Ovarian irradiation, Gonadotropin-releasing hormone agonist)|DRUG: Tamoxifen|DRUG: toremifene
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University